文献速递泌尿男性生殖肿瘤

帕博利珠单抗治疗铂类难治性生殖细胞肿瘤的II期试验

Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206.
PubMed 文献 · Ann Oncol · 2018-01-01

未观察到部分或完全缓解,仅2例影像学稳定但AFP持续升高且PD-L1阴性,结论认为单药活性无临床意义。

要点

  • 帕博利珠单抗在难治性生殖细胞肿瘤中未观察到客观缓解。
  • 仅2例影像学稳定但AFP持续升高且PD-L1阴性。
  • 帕博利珠单抗耐受性良好,无免疫相关不良事件报告。

核心结论

  • 帕博利珠单抗耐受性良好,但在难治性生殖细胞肿瘤中单药无临床意义活性。

研究设计与样本

  • 单臂II期试验,采用Simon两阶段设计,I类错误20%,把握度80%。
  • 帕博利珠单抗200 mg静脉注射每3周一次直至疾病进展。
  • 主要终点为采用免疫相关疗效标准的总体缓解率。

主要发现

  • 中位既往化疗方案数为3,6例曾接受高剂量化疗;2例PD-L1染色阳性(H评分90和170)。
  • 中位帕博利珠单抗给药次数为2次(范围1-8);发生6例3级不良事件,未报告免疫相关不良事件。
  • 未观察到部分或完全缓解;2例影像学稳定分别持续28周和19周,但两者AFP持续升高且PD-L1阴性。

临床怎么用

  • 不推荐帕博利珠单抗单药用于铂类难治性生殖细胞肿瘤的常规治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite remarkable results with salvage standard-dose or high-dose chemotherapy ∼15% of patients with relapsed germ-cell tumors (GCT) are incurable. Immune checkpoint inhibitors have produced significant remission in multiple tumor types. We report the first study of immunotherapy in patients with GCT. PATIENTS AND METHODS: Single arm phase II trial investigating pembrolizumab 200 mg i.v. Q3weeks until disease progression in patients with relapsed GCT and no curable options. Patients age ≥18 with GCT who progressed after first-line cisplatin-based chemotherapy and after at least one salvage regimen (high-dose or standard-dose chemotherapy) were eligible. Centrally assessed programmed death-ligand 1 (PD-L1) on tumor and infiltrating immune cells was scored. Primary end point was overall response rate using immune-related response criteria. Simon two-stage design with type I error 20% and power 80% was utilized. RESULTS: Twelve male patients were enrolled. Median age was 38 years. All patients had nonseminoma. Primary site was testis (11) or mediastinum (1). Median AFP 615 (range 1-32, 760) and hCG 4 (range 0.6-37, 096). Six patients had late relapse (>2 years). Median number of previous chemotherapy regimens was 3. Six patients received prior high-dose chemotherapy. Two patients had positive PD-L1 staining (H-score 90 and 170). Median number of pembrolizumab doses was 2 (range 1-8). There were six grade 3 adverse events. No immune-related adverse events were reported. No partial or complete responses were observed. Two patients achieved radiographic stable disease for 28 and 19 weeks, respectively; both had continued rising AFP level despite radiographic stability and had negative PD-L1 staining. CONCLUSION: This is the first reported trial evaluating immune checkpoint inhibitors in GCT. Pembrolizumab is well tolerated but does not appear to have clinically meaningful single-agent activity in refractory GCT. CLINICAL TRIAL INFORMATION: NCT02499952.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Adra N, Einhorn LH, Althouse SK, et al. Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206. Ann Oncol. 2018. PMID: 29045540. doi:10.1093/annonc/mdx680

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。